Literature DB >> 31613313

First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward.

C Kim1, S V Liu2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31613313     DOI： 10.1093/annonc/mdz415

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  7 in total

1.  Survival Analysis of Antineoplastic Treatment for Older Patients with Metastatic Non-Small-Cell Lung Cancer: A Clinical Database Study.

Authors:  Chin-Hsiu Yu; Ya-Ai Cheng; Ru-Yih Chen; Yu-Lung Wu; Min-Hsi Lin
Journal:  Cancer Manag Res       Date:  2020-12-16       Impact factor: 3.989

2.  Efficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients with EGFR-Mutated Non-Small-Cell Lung Cancer.

Authors:  Cheng-Yu Chang; Chung-Yu Chen; Shih-Chieh Chang; Yi-Chun Lai; Yu-Feng Wei
Journal:  Cancer Manag Res       Date:  2021-09-15       Impact factor: 3.989

3.  A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.

Authors:  Chul Kim; Stephen V Liu; Jennifer Crawford; Tisdrey Torres; Vincent Chen; Jillian Thompson; Ming Tan; Giuseppe Esposito; Deepa S Subramaniam; Giuseppe Giaccone
Journal:  Front Oncol       Date:  2021-09-08       Impact factor: 6.244

4.  EGFR Q787Q Polymorphism Is a Germline Variant and a Prognostic Factor for Lung Cancer Treated With TKIs.

Authors:  Wen-Jui Wu; Sheng-Hsiung Yang; Hsin-Pei Chung; Chia-Te Yen; Yen-Ting Chen; Wei-Chin Chang; Jian Su; Hsuan-Yu Chen
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244

5.  Overdrive pacing in the acute management of osimertinib-induced ventricular arrhythmias: A case report and literature review.

Authors:  Yanyu Zhang; Xingtong Wang; Yilin Pan; Beibei Du; Kumaraswamy Nanthakumar; Ping Yang
Journal:  Front Cardiovasc Med       Date:  2022-09-29

6.  Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.

Authors:  Yock Ping Chow; Norziha Zainul Abidin; Ken Siong Kow; Lye Mun Tho; Chieh Lee Wong
Journal:  PLoS One       Date:  2022-10-18       Impact factor: 3.752

7.  Patient-Reported and End-of-Life Outcomes Among Adults With Lung Cancer Receiving Targeted Therapy in a Clinical Trial of Early Integrated Palliative Care: A Secondary Analysis.

Authors:  Laura A Petrillo; Areej El-Jawahri; Emily R Gallagher; Vicki A Jackson; Jennifer S Temel; Joseph A Greer
Journal:  J Pain Symptom Manage       Date:  2021-02-20       Impact factor: 3.612
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.